Q-omics provides the consensus-scored H3C13 profile across patient tissues and cancer cell-line models. H3C13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, H3C13 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, H3C13 RNA expression shows 19,112 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where H3C13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3C13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3C13 survival associations across molecular data types. H3C13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3C13 RNA expression–survival associations across cancer types. High H3C13 expression shows unfavorable associations in KIRC, UVM, ACC, ESCA, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for H3C13 RNA expression.
This table summarizes H3C13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for H3C13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3C13 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BRCA, READ and BLCA. The HNSC box plot shows higher H3C13 RNA expression in tumor versus normal tissue (log2 FC = +0.412, t-test p < 0.001).
This table shows molecular features associated with H3C13 in patient tissues and cancer cell lines. In patient samples, H3C13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, H3C13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
